本周hzangs在最新文献中选取了7篇分享给大家，第1篇文章介绍了一项多中心临床试验，确认了外泌体活检在早期胃癌检测中的功效；第2篇文章介绍了一种追踪和阻断肿瘤细胞外囊泡的方法；第5篇文章分析了家族性阿尔茨海默病中SORLA在神经营养和外泌体释放中的功能作用。
- Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer: The DESTINEX Multicenter Study.
外泌体液体活检用于早期检测胃癌：DESTINEX 多中心研究。
[JAMA Surg] PMID: 40737022
Abstract: Importance: Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide, primarily attributed to delayed detection. The invasive and cost-prohibitive nature of endoscopy for GC screening highlights the urgent need for noninvasive biomarkers. Objective: To develop an exosome-based diagnostic signature to facilitate blood-based, early detection of patients with GC. Design, setting, and participants: This was a multicenter, population-based, retrospective, case-control study that analyzed specimens collected between January 1, 2016, and December 30, 2020. The study encompassed the discovery, training, validation, and evaluation phases of biomarker development. This study was conducted at 4 major referral centers: Nagoya University Hospital in Japan and Ajou University Hospital, Asan Medical Center, and Samsung Medical Center in South Korea, providing a broad representation of advanced clinical care settings. The study included patients with GC, classified according to the TNM (tumor-node-metastasis) classification (8th edition), and controls without disease. Key sociodemographic data, including age and sex, were recorded for all participants. Data were analyzed from October 2022 to July 2024. Exposures: Results were obtained from tissue and serum microRNA (miRNA) profiling and expression analysis. Frozen tissue collection and blood draws were conducted intraoperatively, preoperatively, and 3 months postoperatively. Main outcomes and measures: Diagnostic performance of GC detection using an exosome-based miRNA signature. Results: A total of 809 specimens from 480 patients (mean [SD] age, 61.9 [9.8] years; 336 male [70%]) in the training and validation cohorts were analyzed. A panel of 8 cell-free miRNAs and 10 exosomal miRNAs was initially developed in the discovery phase, which was subsequently reduced using machine learning algorithms to a panel of 8 cell-free and 9 exosomal miRNAs during the training phase. This 17-miRNA signature robustly identified GC with area under the curve (AUC) values of 96.3% (95% CI, 94.3%-98.4%) and 95.3% (95% CI, 92.8%-97.9%) in the training and validation cohorts, respectively. Additionally, 5 overlapping miRNAs were observed between cell-free and exosomal panels and exhibited a comparable efficacy in identifying patients with GC. Finally, we established a 10-miRNA signature (Destinex), which successfully identified early-stage (pT1) GC (AUC = 96.8%; 95% CI, 93.5%-100%). Finally, a significant decrease in miRNA expression levels in postsurgery serum specimens confirmed the robustness of the panel specificity. Conclusion and relevance: Results of this case-control study suggest that the Destinex assay was robust for early detection of GC, highlighting its potential for clinical application in the noninvasive identification of GC.
- Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles.
通过脂质化纳米光敏剂追踪和禁用肿瘤细胞外囊泡，同时抑制肿瘤生长和转移。
[Nat Cancer] PMID: 40555864
Abstract: Cancer cells promote tumor growth and metastasis through tumor extracellular vesicle (TEV)-mediated intercellular and intertissue communication. Inhibiting TEVs represents a promising strategy to suppress metastasis; however, effectively and selectively disabling TEVs remains challenging. Herein, we developed palmitic acid surface-displayed nanoparticles using an adjacent hydrophilic molecular engineering strategy. Unexpectedly, these lipidated nanoparticles were not only efficiently taken up and distributed within tumor cells but also coupled with TEV generation, enabling active tracing of TEVs. Exploiting their dual tumor spatial distribution (intracellular and intra-TEV), a lipidated nanophotosensitizer was constructed for metastasis therapy. Under near-infrared light irradiation at the primary tumor site, both intracellular and intra-TEV reactive oxygen species were generated synchronously. This led to photodynamic suppression of the primary tumor and blocked intercellular and intertissue communication by disabling TEVs, effectively inhibiting tumor growth and metastasis in multiple tumor models in female mice. Overall, this work reports a therapeutic paradigm for concurrently inhibiting tumor growth and metastasis.
- Labeling, isolation and characterization of cell-type-specific exosomes derived from mouse skin tissue.
来自小鼠皮肤组织的细胞类型特异性外泌体的标记、分离和表征。
[Nat Protoc] PMID: 40940523
Abstract: Extracellular vesicles are a heterogeneous group of membrane-bound vesicles involved in cell-cell communication, formed at the plasma membrane (ectosomes) or by endocytosis (exosomes). Most exosome studies so far have focused on in vitro systems or exosomes derived from bodily fluids, while tissue-derived exosomes remain underexplored. Here we present a protocol using cell-type-specific promoter-driven reporter constructs for the targeted labeling and subsequent isolation of exosomes from specific cell types in vivo from mouse tissues. The differentiation between exosomes and ectosomes remains challenging due to limitations of current isolation techniques that are primarily based on size, density or surface markers. To address this issue, our approach leverages genetic engineering to mark exosomes specifically, enabling their precise identification and isolation from a complex biological pool of heterogenous extracellular vesicles. The isolated cell-type-specific exosomes are characterized by electron microscopy, nanoparticle tracking analysis, antibody exosome array assay and other established techniques. The labeling and isolation of exosomes spans 2-3 days and is designed to be accessible to researchers with fundamental laboratory competencies. This protocol facilitates the study of exosome-mediated cellular communication by enabling the isolation of cell-type-specific exosomes from either individual cell types or multiple cell types in combination. Most experiments within the protocol have used murine wound-edge skin tissue, but the protocol can, in principle, also be applied to other tissues to isolate exosomes, with a few modifications as required. This methodology opens new avenues for exploring the functional roles of cell-type-specific exosomes in intercellular communication.
- Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity.
Parkin 诱导 HMGB1 泛素化和大量细胞外囊泡释放以激活抗肿瘤免疫。
[Cancer Res] PMID: 40928938
Abstract: Parkin is a mitochondria-associated E3 ubiquitin (Ub) ligase that mediates mitophagy and organelle quality control. More recently, Parkin has been implicated in stimulating antitumor immunity and reprogramming the tumor immune microenvironment. Here, we showed that Parkin ubiquitinates the alarmin molecule, high mobility group box-1 (HMGB1) on Lys146 (K146) using predominantly K48 linkages. By molecular modeling, the in-between-ring (IBR) domain of Parkin (Gln326-Leu358) made extensive contacts with the amino-terminus A box of HMGB1 (Met1-Ser42), forming a mitochondria-associated Parkin-HMGB1 complex that juxtaposes K146 to Ub active site residues Gly76 and Arg74. Instead of proteasomal degradation, Parkin ubiquitination of K146 enabled the loading of HMGB1, but not HMGB1 K146A mutant, onto autophagy- and mitochondria-derived large extracellular vesicles (LEV). In turn, released Parkin-HMGB1 LEV stimulated a potent interferon (IFN) and cytokine response in recipient cells, expanding CD8+ T cell subsets with effector (CD69+/KLRG1+), self-renewal (TCF-1+/PD-1+), and cytotoxic (KLRG1+/GrzB+) properties. Conditional expression of Parkin induced HMGB1 release, activated intratumoral CD8+ T cells, and suppressed syngeneic tumor growth in vivo in a response that was abolished by HMGB1 silencing. These data identify that Parkin-LEV regulated release of HMGB1 reprograms antitumor immunity via stimulation of IFN signaling and expansion of specialized CD8+ T cell subsets.
- Familial Alzheimer's disease mutation identifies novel role of SORLA in release of neurotrophic exosomes.
家族性阿尔茨海默病突变确定了 SORLA 在神经营养外泌体释放中的新作用。
[Alzheimers Dement] PMID: 40928027
Abstract: Introduction: Mutations in SORL1, encoding the sorting receptor Sortilin-related receptor with A-type repeats (SORLA), are found in individuals with Alzheimer's disease (AD). We studied SORLAN1358S, carrying a mutation in its ligand binding domain, to learn more about receptor functions relevant for human brain health. Methods: We investigated consequences of SORLAN1358S expression in induced pluripotent stem cell (iPSC)-derived human neurons and microglia, using unbiased proteome screens and functional cell assays. Results: We identified alterations in the SORLAN1358S interactome linked to biogenesis of exosomes. Consequently, the mutant receptor failed to promote release and neurotrophic qualities of exosomes, a defect attributed to altered exosomal content of microRNAs controlling neuronal maturation. Discussion: We identified a role for SORLA in controlling quantity and neurotrophic quality of exosomes secreted by cells, suggesting impaired cellular cross talk through exosomes as a pathological trait contributing to AD pathology in carriers of SORL1 variants.
- Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.
外膜囊泡作为疫苗开发的多功能平台：工程策略、应用和挑战。
[J Extracell Vesicles] PMID: 40919883
Abstract: Outer membrane vesicles (OMVs) are nanosized vesicles naturally secreted by Gram-negative bacteria and represent a promising platform for vaccine development. OMVs possess inherent immunostimulatory properties due to the presence of pathogen-associated molecular patterns (PAMPs), providing self-adjuvanting capabilities and the ability to elicit both innate and adaptive immune responses. This review outlines the advantages of OMVs over traditional vaccine strategies, including their safety, modularity, and the potential for genetic engineering to enable targeted antigen delivery. We describe approaches to enhance OMVs yield and immunogenicity, such as modifications to reduce lipopolysaccharide (LPS) toxicity and systems enabling antigen localization-either on the surface or within the lumen-using fusion constructs like ClyA, Lpp-OmpA, AIDA-I, Hbp, and Sec/Tat signal peptides. We further summarize preclinical applications of OMVs-based vaccines targeting bacterial pathogens, viral infections, and cancer. In addition, we address key challenges in large-scale production, purification, and long-term stability, and explore strategies for conjugating or encapsulating heterologous antigens. Overall, OMVs offer a versatile and scalable extracellular vesicle-based platform with strong potential for next-generation vaccines targeting diverse infectious diseases and beyond.
- Small extracellular vesicles orchestrated pathological communications between breast cancer cells and cardiomyocytes as a novel mechanism exacerbating anthracycline cardiotoxicity by fueling ferroptosis.
小细胞外囊泡协调乳腺癌细胞和心肌细胞之间的病理通讯，作为一种新机制，通过促进铁死亡而加剧蒽环类药物的心脏毒性。
[Redox Biol] PMID: 40915108
Abstract: Small extracellular vesicles (sEVs) critically orchestrate inter-tissue and inter-organ communications and may play essential roles in heart-tumor interaction. However, whether cancer-secreted sEVs affect the progression of doxorubicin-induced cardiotoxicity (DOXIC) via orchestrating the tumor cell-cardiomyocyte crosstalk has not yet been explored. Herein, we reveal that Doxorubicin (DOX)-treated breast cancer cells secrete sEVs (D-BCC-sEVs) that exacerbate DOX-induced ferroptosis of human iPSC-derived cardiomyocytes (hiCMs). miRNA expression profiling and experimental validations reveal that miR-338-3p is upregulated in D-BCC-sEVs and mediate its detrimental effects. Incubation of hiCMs with D-BCC-sEVs or overexpression of miR-338-3p alone intensifies DOX-induced ferroptosis. N6-methyladenosine (m6A) is revealed to mediate the upregulation of miR-338-3p in D-BCCs. D-BCCs-enriched miR-338-3p is packaged in sEVs and transferred into hiCMs in a RBMX-dependent manner, miR-338-3p further targets anti-ferroptotic genes CP, SLC7A11, and GPX4 to facilitate their degradation. Therapeutically, dual-functional decoying sEVs encapsulated with miR-338-3p inhibitor mitigate DOXIC in an orthotopic breast cancer mouse model. Clinically, plasma sEVs isolated from patients experiencing DOXIC enhance DOX-induced ferroptosis in hiCM, which is rescued by miR-338-3p inhibitor. Our findings uncovered for the first time that DOX-treated BCCs exacerbated DOXIC through releasing pro-ferroptotic miR-338-3p-enriched sEVs. Therefore, targeting sEVs-mediated tumor/cardiomyocyte pathological communication may offer a novel approach for the management of DOXIC.
今天的整理就到这里。希望大家可以有所收获。大家下周见！
